Jefferies analyst Gena Wang upgraded Intellia Therapeutics to Buy following the company's Q2 results. The company has "transformative" gene-editing technology and has enough cash to support operation through 2020, Wang tells investors in a post-earnings research note. The analyst keeps a $33 price target for the shares.

08/05/16

LEER

08/05/16UPGRADETarget $32LEEROutperform

Intellia Therapeutics upgraded to Outperform from Market Perform at Leerink

Leerink analyst Michael Schmidt upgraded Intellia Therapeutics to Outperform from Market Perform on valuation. The analyst believes the stock's current valuation represents an attractive entry point to own "one of the most exciting" technology platforms Biotech has to offer. Schmidt says Intellia Therapeutics is a leader in the development of CRISPR/Cas9-based genome editing therapeutics, and believes its platform has disruptive potential that could expand the potential of existing genome therapeutics. He has a $32 price target on the shares.

08/22/16

WEDB

08/22/16NO CHANGEWEDB

Intellia Therapeutics data positive, says Wedbush

Wedbush analyst David Nierengarten says that additional data on Intella's (NTLA) TTR program in mice was "meaningful" and indicates that the program compares favorably with competing products. The analyst says that competing programs, including those of Alnylam (ALNY) and Ionis (IONS) have shown "only a transient benefit." He reiterates a $38 price target and Outperform rating on Intella.